Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.67)
# 798
Out of 5,091 analysts
81
Total ratings
58.21%
Success rate
28.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $20 → $12 | $14.17 | -15.28% | 5 | Sep 15, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $510 → $475 | $442.04 | +7.46% | 19 | Sep 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $280 → $515 | $430.02 | +19.77% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: In-Line | $3 → $2 | $6.47 | -69.09% | 5 | May 28, 2025 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $57.36 | +72.59% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $34.29 | +31.23% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $7.70 | +55.84% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $2.42 | +106.61% | 5 | Dec 16, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $41.55 | -15.76% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $568.57 | -36.68% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.10 | +81.82% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $54.65 | -30.47% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $36.45 | +119.48% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $13.00 | +38.46% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $5.61 | +345.63% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $6.40 | +446.88% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $45.03 | -46.70% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $18.12 | +65.56% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $4.52 | +121.24% | 1 | Feb 5, 2020 |
Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $14.17
Upside: -15.28%
Vertex Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $510 → $475
Current: $442.04
Upside: +7.46%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280 → $515
Current: $430.02
Upside: +19.77%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $6.47
Upside: -69.09%
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $57.36
Upside: +72.59%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $34.29
Upside: +31.23%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $7.70
Upside: +55.84%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $2.42
Upside: +106.61%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $41.55
Upside: -15.76%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $568.57
Upside: -36.68%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.10
Upside: +81.82%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $54.65
Upside: -30.47%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $36.45
Upside: +119.48%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $13.00
Upside: +38.46%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $5.61
Upside: +345.63%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $6.40
Upside: +446.88%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $45.03
Upside: -46.70%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $18.12
Upside: +65.56%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $4.52
Upside: +121.24%